TargoPep grew from the world-leading advances being researched in the Burley Research Group out of the University of Strathclyde’s Pure and Applied Chemistry. Under the directorship of Prof. Glenn Burley the team was looking into enabling the delivery of morpholino oligomers (PMOs) using short peptide-based sequences with tuned, non-natural building blocks. The team tied together the fields of Chemical Biology and Medicinal Chemistry by collaborating with Prof. Simon Mackay to apply validated drug design to these more traditional ‘biologic’ approaches.